Tiansheng Pharmaceutical Group Co., Ltd. (SHE:002872)
China · Delayed Price · Currency is CNY 5.42
-0.02 (-0.37%)
Apr 30, 2026, 3:04 PM CST
SHE:002872 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 514.09 | 528.9 | 540.56 | 577.23 | 712.93 |
Other Revenue | - | 40.81 | 38.78 | 29.76 | 23.75 |
| 514.09 | 569.71 | 579.33 | 606.99 | 736.69 | |
Revenue Growth (YoY) | -9.76% | -1.66% | -4.56% | -17.61% | -38.75% |
Cost of Revenue | 261.59 | 308.57 | 322.36 | 279.1 | 441.56 |
Gross Profit | 252.5 | 261.14 | 256.97 | 327.89 | 295.12 |
Selling, General & Admin | 274.37 | 298.51 | 312.22 | 392 | 328.41 |
Research & Development | 22.32 | 22.75 | 30.92 | 34.27 | 29.24 |
Other Operating Expenses | -5.96 | 1.22 | -4.44 | -6 | -7.68 |
Operating Expenses | 290.73 | 321.7 | 342.93 | 421.54 | 367.56 |
Operating Income | -38.23 | -60.56 | -85.96 | -93.65 | -72.44 |
Interest Expense | - | -14.78 | -14.99 | -15.78 | -24.36 |
Interest & Investment Income | 6.08 | 24.1 | 10.08 | 12.63 | 21.8 |
Other Non Operating Income (Expenses) | -19.67 | -22.7 | -4.67 | -9.5 | -1.83 |
EBT Excluding Unusual Items | -51.81 | -73.95 | -95.55 | -106.31 | -76.82 |
Impairment of Goodwill | - | - | - | - | -2.49 |
Gain (Loss) on Sale of Investments | 0.16 | 1.18 | 0.33 | -0.19 | -0.39 |
Gain (Loss) on Sale of Assets | -0.16 | 0.04 | 0.23 | 9.53 | 5.22 |
Asset Writedown | -10.02 | -24.18 | -4.81 | -3.21 | -5.99 |
Other Unusual Items | - | -0.89 | 5.07 | 16.07 | 26.03 |
Pretax Income | -61.83 | -97.79 | -94.72 | -84.12 | -54.44 |
Income Tax Expense | -5.82 | -9.64 | -1.01 | 7.44 | 17.89 |
Earnings From Continuing Operations | -56.01 | -88.15 | -93.71 | -91.55 | -72.34 |
Minority Interest in Earnings | 0.59 | 0.74 | 0.64 | 0.99 | 4.53 |
Net Income | -55.42 | -87.4 | -93.07 | -90.56 | -67.81 |
Net Income to Common | -55.42 | -87.4 | -93.07 | -90.56 | -67.81 |
Shares Outstanding (Basic) | 318 | 318 | 318 | 318 | 318 |
Shares Outstanding (Diluted) | 318 | 318 | 318 | 318 | 318 |
Shares Change (YoY) | 0.01% | -0.01% | -0.00% | -0.01% | 0.01% |
EPS (Basic) | -0.17 | -0.27 | -0.29 | -0.28 | -0.21 |
EPS (Diluted) | -0.17 | -0.27 | -0.29 | -0.28 | -0.21 |
Free Cash Flow | 16.05 | -0.13 | -101.3 | 15.76 | -95.41 |
Free Cash Flow Per Share | 0.05 | - | -0.32 | 0.05 | -0.30 |
Gross Margin | 49.12% | 45.84% | 44.36% | 54.02% | 40.06% |
Operating Margin | -7.44% | -10.63% | -14.84% | -15.43% | -9.83% |
Profit Margin | -10.78% | -15.34% | -16.07% | -14.92% | -9.20% |
Free Cash Flow Margin | 3.12% | -0.02% | -17.49% | 2.60% | -12.95% |
EBITDA | 82.74 | 45.11 | 18.21 | 11.85 | 14.92 |
EBITDA Margin | 16.10% | 7.92% | 3.14% | 1.95% | 2.02% |
D&A For EBITDA | 120.97 | 105.67 | 104.17 | 105.51 | 87.36 |
EBIT | -38.23 | -60.56 | -85.96 | -93.65 | -72.44 |
EBIT Margin | -7.44% | -10.63% | -14.84% | -15.43% | -9.83% |
Revenue as Reported | - | 569.71 | 579.33 | 606.99 | 736.69 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.